Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 11, 2023 16:01 ET | Source: VYNE Therapeutics Inc.

VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Anticipate topline 16-week data for all three cohorts from the Phase 1b trial for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo in the third quarter of 2023 IND-enabling studies for VYN202,...
May 01, 2023 08:00 ET | Source: VYNE Therapeutics Inc.

VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions

Preclinical studies suggest VYN202 has the potential to be the most potent and selective BET inhibitor in development VYN202 has demonstrated a potent anti-inflammatory and anti-fibrotic effect in...
April 19, 2023 08:00 ET | Source: VYNE Therapeutics Inc.

VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis

VYN201 at the 0.5 mg/ml and 1 mg/ml doses demonstrated statistically significant reductions in lung fibrosis and hydroxyproline levels compared to placeboReduction in lung fibrosis from VYN201...
March 30, 2023 07:45 ET | Source: VYNE Therapeutics Inc.

VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201

No quantifiable VYN201 plasma concentrations above the assay lower limit of quantification supports “soft” drug approach for topical pan-BD BET inhibitor All hematological parameters, including...
March 22, 2023 08:00 ET | Source: VYNE Therapeutics Inc.

VYNE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference

BRIDGEWATER, N.J., March 22, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary,...
March 09, 2023 16:01 ET | Source: VYNE Therapeutics Inc.

VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update

First vitiligo patients being treated with pan-BD BET inhibitor, VYN201, for up to 16 weeks in Phase 1b clinical trial Anticipate topline Phase 1b data in mid-2023 BRIDGEWATER, N.J., March 09,...
February 28, 2023 16:00 ET | Source: VYNE Therapeutics Inc.

VYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

BRIDGEWATER, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary,...
February 22, 2023 08:00 ET | Source: VYNE Therapeutics Inc.

VYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference

BRIDGEWATER, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative,...
February 15, 2023 08:00 ET | Source: VYNE Therapeutics Inc.

VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201

VYN201 was generally well-tolerated with no clinically relevant treatment emergent adverse events from all dose cohorts, meeting the primary objective of the study Topline Phase 1b results in...
February 10, 2023 08:00 ET | Source: VYNE Therapeutics Inc.

VYNE Therapeutics Announces Reverse Stock Split

BRIDGEWATER, N.J., Feb. 10, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and...